OS Therapies Inc

OSTX NYSE SEC CIK 1795091
Follow OS Therapies Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$11.3M −64% vs same quarter last year
EPS, diluted −$0.23 −4.5% vs same quarter last year
Operating cash flow −$4.7M +1.1% vs same quarter last year
Operating income −$9M −31.3% vs same quarter last year
Net income by quarter
−$3M
−$3.9M
−$4.5M
−$6.9M
−$13.5M
−$10.4M
−$8.6M
−$11.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
−$30M−$20M−$10M$0FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$28.8M
FY24−$8.9M
FY23−$7.8M
FY22-